Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.50 |
| ▸ | CES2 | O00748 | 1/20 | 0.47 |
| ▸ | CES1 | P23141 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.42 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
| ▸ | ACACB | O00763 | 1/20 | 0.42 |
| ▸ | ACACA | Q13085 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | ACP3 | P15309 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL68152 | 0.89 | KMT2A (0.64) | KMT2APTGS2CES2CES1ALDH1A1 | |
| SCHEMBL318731 | 0.89 | KMT2A (0.64) | KMT2APTGS2CES2CES1ALDH1A1 | |
| SCHEMBL319987 | 0.89 | KMT2A (0.64) | KMT2APTGS2CES2CES1ALDH1A1 | |
| SCHEMBL13522785 | 0.85 | KMT2A (0.51) | KMT2APTGS2CES2CES1 | |
| SCHEMBL1565875 | 0.83 | MAPK1 (0.51) | KMT2ACES2CES1ALDH1A1ACACB | |
| SCHEMBL7437238 | 0.81 | PTGS2 (0.61) | PTGS2CES2CES1CYP1A2GAA | |
| SCHEMBL7571366 | 0.80 | KMT2A (0.53) | KMT2APTGS2ALDH1A1CYP3A4CYP1A2 | |
| SCHEMBL7564000 | 0.80 | KMT2A (0.53) | KMT2APTGS2ALDH1A1CYP3A4CYP1A2 | |
| SCHEMBL4827831 | 0.80 | PTGS2 (0.67) | KMT2APTGS2ALDH1A1CYP3A4CYP1A2 | |
| SCHEMBL7567588 | 0.80 | KMT2A (0.53) | KMT2APTGS2ALDH1A1CYP3A4CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023173618-A1 | CYCLIC GD (III) COMPLEX, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 国科温州研究院(温州生物材料与工程研究所) | 2023-09-21 | — | — | WO | disclosed |
| US-9522893-B2 | Therapeutic methods and compounds | AMPIO PHARMACEUTICALS, INC. (US) | 2016-12-20 | — | — | US | disclosed |
| US-20150051224-A1 | THERAPEUTIC METHODS AND COMPOUNDS | AMPIO PHARMACEUTICALS, INC. | 2015-02-19 | — | — | US | disclosed |
| US-8871772-B2 | Therapeutic methods and compounds | AMPIO PHARMACEUTICALS, INC. (US) | 2014-10-28 | — | — | US | disclosed |
| US-8217047-B2 | Therapeutic methods and compounds | DMI ACQUISITION CORP. (US) | 2012-07-10 | — | — | US | disclosed |
| US-20120157473-A1 | THERAPEUTIC METHODS AND COMPOUNDS | DMI ACQUISITION CORP. (US) | 2012-06-21 | — | — | US | disclosed |
| EP-2300011-A1 | THERAPEUTIC METHODS AND COMPOUNDS | DMI Life Sciences, Inc. (US) | 2011-03-30 | — | — | EP | disclosed |
| US-20100105698-A1 | Therapeutic Methods and Compounds | DMI LIFE SCIENCES, INC. (US) | 2010-04-29 | — | — | US | disclosed |
| WO-2009146320-A1 | THERAPEUTIC METHODS AND COMPOUNDS | DMI LIFE SCIENCES, INC. (US) | 2009-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105698-A1 | Therapeutic Methods and Compounds | MMP9, MMP17, MMP1 | KMT2A 2053/4885PTGS2 555/4885CES2 2805/4885 |
| US-20120157473-A1 | THERAPEUTIC METHODS AND COMPOUNDS | MMP9, MMP17, MMP1 | KMT2A 2053/4885PTGS2 555/4885CES2 2805/4885 |
| US-20150051224-A1 | THERAPEUTIC METHODS AND COMPOUNDS | MMP9, MMP17, MMP1 | KMT2A 2053/4885PTGS2 555/4885CES2 2805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.